We are studying a new treatment combination for patients with relapsed or refractory diffuse large B-cell lymphoma. The focus is on understanding the safety and frequency of cytokine release syndrome with this therapy.
Health conditions and diseases that the clinical trial is designed to study and treat.
Refractory Diffuse Large B-Cell Lymphoma (DLBCL) is a type of aggressive non-Hodgkin lymphoma that does not respond to initial treatment, leading to a return of the disease. It can cause symptoms such as swollen lymph nodes, fever, night sweats, and unexplained weight loss.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
